Proteinuria and favourable clinical response in a patient receiving paclitaxel + bevacizumab for metastatic breast cancer

Annals of Oncology

Volumn 21, Issue 8, 2010, Pages 1729-1730

  Karachaliou, N ^a   Saloustros, E ^a   Vamvakas, L ^a   Mavroudis, D ^a   Georgoulias, V ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CREATININE; FUROSEMIDE; PACLITAXEL;

AGED; ANAMNESIS; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CASE REPORT; CREATININE BLOOD LEVEL; CREATININE URINE LEVEL; DRUG RESPONSE; DRUG WITHDRAWAL; EDEMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LEG EDEMA; LETTER; LYMPH NODE BIOPSY; LYMPH NODE METASTASIS; LYMPHADENOPATHY; MEDIASTINOSCOPY; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; PATIENT MONITORING; PRIORITY JOURNAL; PROTEINURIA; RETREATMENT; SACRUM EDEMA; SIDE EFFECT;

EID: 77955246717     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq328     Document Type: Letter

References (5)

1. Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
2. Gerber HP, Wu X, Yu L et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc Natl Acad Sci U S A 2007; 104: 3478-3483.
3. George BA, Zhou XJ, Toto R. Nephrotic syndrome after bevacizumab: case report and literature review. Am J Kidney Dis 2007; 49: e23-e29.
4. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Eng J Med 2008; 358: 1129-1136.
5. Scartozzi M, Galizia E, Chiorrini S et al. Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab. Ann Oncol 2009; 20: 227-230.